Financials in USD. Standardized financial statements.
A compact view of how Y-mAbs Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $87.69M | $84.82M | $65.27M | $34.90M | $20.75M | $0 | $0 | $0 | $0 |
| Revenue Growth? | +3.4% | +30.0% | +87.0% | +68.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $15.25M | $11.42M | $7.57M | $2.51M | $2.20M | $166,000 | $29,000 | $0 | $0 |
| Gross Profit? | $72.43M | $73.40M | $57.70M | $32.38M | $18.55M | -$166,000 | -$29,000 | $0 | $0 |
| Gross Margin? | +82.6% | +86.5% | +88.4% | +92.8% | +89.4% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $103.64M | $99.08M | $152.51M | $147.82M | $138.48M | $83.00M | $43.23M | $19.24M | $17.04M |
| Operating Income? | -$31.20M | -$25.67M | -$94.81M | -$115.43M | -$119.94M | -$83.00M | -$43.23M | -$19.24M | -$17.04M |
| EBITDA? | -$30.67M | -$24.94M | -$94.73M | -$54.49M | -$119.54M | -$82.84M | -$43.20M | $83,000 | -$18,000 |
| Income Before Tax | -$29.81M | -$20.87M | -$95.57M | -$55.27M | -$119.34M | -$81.03M | -$43.27M | -$19.16M | -$17.06M |
| Income Tax Expense | -$146,000 | $561,000 | $0 | $0 | $0 | $0 | -$44,000 | $0 | $0 |
| Net Income? | -$29.67M | -$21.43M | -$95.57M | -$55.27M | -$119.34M | -$78.89M | -$43.27M | -$19.16M | -$17.06M |
| EPS? | $-0.67 | $-0.49 | $-2.20 | $-1.28 | $-2.97 | $-2.24 | $-1.50 | $-0.58 | $-0.97 |
| Diluted EPS? | $-0.67 | $-0.49 | $-2.20 | $-1.28 | $-2.97 | $-2.24 | $-1.50 | $-0.58 | $-0.97 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality